CHCHD2 mutant mice link mitochondrial deficits to PD pathophysiology

CHCHD2突变小鼠将线粒体缺陷与帕金森病病理生理学联系起来

阅读:10
作者:Szu-Chi Liao ,Kohei Kano ,Sadhna Phanse ,Mai Nguyen ,Elyssa Margolis ,YuHong Fu ,Jonathan X Meng ,Mohamed Taha Moutaoufik ,Zac Chatterton ,Tatiana Saccon ,Kirsten Broderick ,Hiroyuki Aoki ,Jeffrey Simms ,Felicia Xaveria Suteja ,Yoshitaka Sei ,Eric J Huang ,Kevin McAvoy ,Giovanni Manfredi ,Glenda Halliday ,Mohan Babu ,Ken Nakamura

Abstract

Mitochondrial dysfunction is a hallmark of Parkinson's disease (PD), but the mechanisms by which it drives autosomal dominant and idiopathic forms of PD remain unclear. To investigate this, we generated and performed a comprehensive phenotypic analysis of a knock-in mouse model carrying the T61I mutation in the mitochondrial protein CHCHD2 (coiled-coil-helix-coiled-coil-helix domain-containing 2), which causes late-onset symptoms indistinguishable from idiopathic PD. We observed pronounced mitochondrial disruption in substantia nigra dopaminergic neurons, including distorted ultrastructure and CHCHD2 aggregation, as well as disrupted mitochondrial protein-protein interactions in brain lysates. These abnormalities were associated with a whole-body metabolic shift toward glycolysis, elevated mitochondrial reactive oxygen species (ROS), and progressive accumulation of aggregated α-synuclein. In idiopathic PD, CHCHD2 gene expression also correlated with α-synuclein levels in vulnerable dopaminergic neurons, and CHCHD2 protein accumulated in early Lewy aggregates. These findings delineate a pathogenic cascade in which CHCHD2 accumulation impairs mitochondrial respiration and increases ROS production, driving α-synuclein aggregation and neurodegeneration.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。